Alzamend Neuro Announced Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Source :: Plus Company Updates. March 23, 2023
Publication Year :: 2023
Abstract: ATLANTA: Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder, major depressive disorder (MDD) [...]

Subjects :: Bipolar disorder -- Drug therapy
Alzheimer's disease -- Drug therapy
Clinical trials
Post-traumatic stress disorder -- Drug therapy
General interest
News, opinion and commentary

Tools